Posted by Site Administrator on August 13, 2012
Chaim Lebovits, CEO and president of BrainStorm Cell Therapeutics in Israel, discusses the potential for the company’s developmental therapy and its implications for patients with ALS. He is joined in this segment by Rasheda Ali, daughter of Muhammad Ali, and an advisory board member for BrainStorm.
Categories: Research News, Technology, Treatments
|
Tags: ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, BrainStorm Cell Therapeutics, Chaim Lebovits, Hadassah Medical Center, Lou Gehrig's disease, Massachusetts General Hospital, Muhammad Ali, NurOwn, RASCALS Foundation, Rasheda Ali, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
|
No comments
Posted by Site Administrator on August 13, 2012
“We are moved by the remarkable results observed following treatment with NurOwn,” said Professor Avi Israeli, BrainStorm’s Chairman of the Board. “We are hopeful that we will continue to see this kind of improvement in all the patients participating in our current and future clinical trials.”
Categories: Research News, Technology, Treatments
|
Tags: ALS, ALS community, ALS orphan drug designation status, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, BrainStorm Cell Therapeutics, compassionate use ALS, Hadassah Medical Center, Lou Gehrig's disease, Massachusetts General Hospital, NurOwn, Phase 1 and II clinical trial, Professor Avi Israeli, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, University of Massachusetts Medical School
|
No comments